TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

Rachel A. Freedman, Nancy U. Lin, Michelle Melisko et al.|Journal of Clinical Oncology|2017

Cited by 36